PELNSEPiramal Enterprises Limited· PharmaceuticalsHighPositive
Announced Tue, 6 May · 17:27 IST

Piramal Enterprises Limited has informed the Exchange that Board of Directors at its meeting held on May 06, 2025, recommended Final Dividend of Rs. 11 per equity share.

Emphasis Of MatterRevenue DeclinePat NegativeExceptional ItemResults View source PDF
Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Piramal Enterprises' Board, at its May 6, 2025 meeting, approved audited standalone and consolidated financial results for FY ended March 31, 2025, and recommended a final dividend of Rs. 11 per share (550% on face value of Rs. 2), subject to shareholder approval. On a standalone basis, FY25 total income fell sharply to Rs. 2,257.94 crore from Rs. 3,825.21 crore in FY24, mainly because the previous year included one-time gains from the sale of Shriram Group stakes. Despite the lower revenue, standalone profit after tax rose modestly to Rs. 503.73 crore (vs. Rs. 474.05 crore) helped by a Rs. 408.51 crore reversal of impairment provisions. Q4 FY25 standalone results, however, slipped into a loss of Rs. 23.33 crore. Auditors issued an unmodified (clean) opinion, but flagged two Emphasis of Matter notes related to Piramal Finance's conversion from HFC to NBFC-ICC and recognition of deferred tax assets on past losses.

Likely market impact

The final dividend of Rs. 11 per share offers a meaningful yield signal, but the steep year-on-year drop in total income and a Q4 standalone loss may weigh on sentiment. Asset quality remains reasonable (Gross NPA 3.18%, Net NPA 0.93%), and the conversion of subsidiary PFL to an NBFC-ICC plus the composite scheme of arrangement could reshape the group's structure going forward.